IMUNON (IMNN, Financial) has announced that its new analysis of overall survival data from the Phase 2 OVATION 2 study involving IMNN-001, a treatment for advanced ovarian cancer, will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This meeting is scheduled for May 30 through June 3, 2025, in Chicago, Illinois, with options for virtual attendance.
The company has also reported a recent alignment with the U.S. Food and Drug Administration (FDA) on the study protocol for its subsequent trial, the Phase 3 OVATION 3 clinical trial of IMNN-001, which is now in the process of activating trial sites. This development marks a significant step forward in their ongoing efforts to treat women with newly diagnosed advanced ovarian cancer.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Imunon Inc (IMNN, Financial) is $13.60 with a high estimate of $29.00 and a low estimate of $5.00. The average target implies an upside of 1,428.09% from the current price of $0.89. More detailed estimate data can be found on the Imunon Inc (IMNN) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, Imunon Inc's (IMNN, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Imunon Inc (IMNN, Financial) in one year is $0.43, suggesting a downside of 51.69% from the current price of $0.89. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Imunon Inc (IMNN) Summary page.
